The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double‐blind study of denosumab and zoledronic acid
Abstract
BACKGROUND: In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases. METHODS: The prevention of pain, reduction in pain interference with daily life activities, and the proportion of patients requiring strong opioid analgesics were assessed in a randomized, double‐blind, double‐dummy phase 3 study comparing denosumab with ZA for preventing skeletal‐related events in 2046 patients who had breast cancer and bone metastases. Patients completed the Brief Pain Inventory‐Short Form at baseline and monthly thereafter. RESULTS: Fewer patients who received denosumab reported a clinically meaningful worsening of pain severity (≥2‐point increase) from baseline compared with patients who received ZA, and a trend was observed toward delayed time to pain worsening with denosumab versus ZA (denosumab, 8.5 months; ZA, 7.4 months; P = .08). In patients who had no/mild pain at baseline, a 4‐month delay in progression to moderate/severe pain was observed with denosumab compared with ZA (9.7 months vs 5.8 months; P = .002). Denosumab delayed the time to increased pain interference by approximately 1 month compared with ZA (denosumab, 16.0 months; ZA, 14.9 months; P = .09). The time to pain improvement ( P = .72) and the time to decreased pain interference ( P = .92) were similar between the groups. Fewer denosumab‐treated patients reported increased analgesic use from no/low use at baseline to strong opioid use. CONCLUSIONS: Denosumab demonstrated improved pain prevention and comparable pain palliation compared with ZA. In addition, fewer denosumab‐treated patients shifted to strong opioid analgesic use. Cancer 2013. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471 · cited 1×
“A common, distribution-based approach to determining the MID is to use one-half of the standard deviation (SD) for the measure.(17) One-half of the SD for worst pain at”
BackgroundSelf-citation
Cited by
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C., Craig, D., Gafford, E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 621
Self-citationBone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Self-citationBisphosphonates and other bone agents for breast cancer
O'Carrigan, B., Wong, M. H., Willson, M. L., Stockler, M. R., Pavlakis, N., & Goodwin, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474.pub4 · Cited by 356
Swarm, R., Abernethy, A. P., Anghelescu, D. L., Benedetti, C., Blinderman, C. D., Boston, B., Cleeland, C., Coyle, N., deLeon-Casasola, O. A., Eilers, J. G., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0076 · Cited by 319
Self-citationCleeland, C. S., Mayer, M., Dreyer, N. A., Yim, Y. M., Yu, E., Su, Z., Mun, Y., Sloan, J. A., & Kaufman, P. A. (2014) · The Breast · doi:10.1016/j.breast.2014.08.004 · Cited by 75
Self-citation
Metadata
- Authors
- Cleeland, C. S., Body, J., Stopeck, A., von Moos, R., Fallowfield, L., Mathias, S. D., Patrick, D. L., Clemons, M., Tonkin, K., Masuda, N., Lipton, A., de Boer, R., Salvagni, S., Oliveira, C. T., Qian, Y., Jiang, Q., Dansey, R., Braun, A., & Chung, K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-09-05
- Volume
- 119
- Issue
- 4
- Pages
- 832-838
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1607511023
- Cited by
- 159
- References
- 2
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double‐blind study of denosumab and zoledronic acid. https://app.cochat.ai/papers/10.1002/cncr.27789
- The paper
- Cleeland, C. S., Body, J., Stopeck, A., von Moos, R., Fallowfield, L., Mathias, S. D., Patrick, D. L., Clemons, M., Tonkin, K., Masuda, N., Lipton, A., de Boer, R., Salvagni, S., Oliveira, C. T., Qian, Y., Jiang, Q., Dansey, R., Braun, A., & Chung, K. (2013). Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double‐blind study of denosumab and zoledronic acid. Cancer. https://doi.org/10.1002/cncr.27789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.